Beth Eaby-Sandy
Hospital of the University of Pennsylvania
6 Papers
1 Citations
Beth Eaby-Sandy is an academic researcher from Hospital of the University of Pennsylvania. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
EGFR fusions as novel therapeutic targets in lung cancer
Kartik Konduri,Jean-Nicolas Gallant,Young Kwang Chae,Francis J. Giles,Barbara J. Gitlitz,Kyle Gowen,Eiki Ichihara,Taofeek K. Owonikoko,Vijay Peddareddigari,Suresh S. Ramalingam,Satyanarayan K. Reddy,Beth Eaby-Sandy,Tiziana Vavalà,Andrew Whiteley,Heidi Chen,Yingjun Yan,Jonathan H. Sheehan,Jens Meiler,Deborah Morosini,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Siraj M. Ali,Christine M. Lovly +23 more
TL;DR: The identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer are reported and responses to the EGFR inhibitor erlotinib are documented in 4 patients whose tumors harbored EGFR fusions.
119
Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.
TL;DR: Prevention and management of toxicities can allow patients to remain on therapy and hence receive maximum clinical benefit from the drug.
Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis.
TL;DR: The current literature surrounding the use of targeted therapies and immunotherapies in patients undergoing active hemodialysis while being treated for lung cancer is outlined.
Use of Diagnostic Tests in Advanced Non-Small Cell Lung Cancer.
TL;DR: Part 1 of an accredited educational activity based on the recently concluded APSHO Regional Lecture Series is offered, essentials skills of interpreting pathology reports and imaging studies are reviewed.
A new targeted treatment for lung cancer patients.
TL;DR: While this gene rear-ragement is uncommon, the test for EML4-ALK should be considered for all NSCLC patients with adenocarci-noma histology who have adequate tissue for sampling, and a rebiopsy should strongly be considered if there is inadequate tissue available for testing.